NGNE: Neurogene Inc. Stock

by  •  • Comments Off on NGNE: Neurogene Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 169.60
Enterprise Value ($M) 33.01
Book Value ($M) 310.38
Book Value / Share 20.79
Price / Book 0.55
NCAV ($M) 290.57
NCAV / Share 19.46
Price / NCAV 0.58

Profitability (mra)
Return on Invested Capital (ROIC) -0.23
Return on Assets (ROA) -0.38
Return on Equity (ROE) -0.44

Liquidity (mrq)
Quick Ratio 20.84
Current Ratio 20.84

Balance Sheet (mrq) ($M)
Current Assets 315.92
Assets 335.73
Liabilities 25.36
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.93
Operating Income -82.61
Net Income -75.14
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -70.60
Cash from Investing -125.26
Cash from Financing 184.07

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Redmile Group, LLC 9.90 40.89
02-14 13G/A Great Point Partners Llc 2.98 -55.91
02-14 13G/A Rtw Investments, Lp 9.99 32.03
02-14 13G/A Janus Henderson Group Plc 0.00 -100.00
02-14 13G/A Casdin Capital, LLC 8.70 26.42
12-11 13G Commodore Capital Lp 5.40
11-27 13G/A Samsara BioCapital, L.P. 11.60 33.88
11-14 13G/A Cormorant Asset Management, LP 0.83 -85.61
11-12 13G Fmr Llc 5.63

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-16 21,235 91,099 23.31
2025-04-15 50,735 143,643 35.32
2025-04-14 93,540 254,814 36.71
2025-04-11 285,694 625,725 45.66

(click for more detail)

Similar Companies
NAII – Natural Alternatives International, Inc. NAMS – NewAmsterdam Pharma Company N.V.
NEUP – Neuphoria Therapeutics Inc. NRIX – Nurix Therapeutics, Inc.
NTLA – Intellia Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io